For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.

Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.

Scholar Rock announced it closed on a Series C financing worth $47 million, with the round led by new investor Invus.

Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Biogen’s staggering price tag for the spinal muscular atrophy drug Spinraza is likely to further ignite the controversies of drug pricing.

Biogen and Ionis Pharma announced that Spinraza (nusinersen) met its primary endpoint in its Phase III trial in later-onset spinal muscular atrophy (SMA).

Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.